Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Biogen Idec Research Limited
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Efficacy and Safety of BIIB074 in Participants with Trigeminal Neuralgia
The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with TN. The primary objective of the LTE phase of the study is to evaluate the lon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
An extension study for patients with Spinal Muscular Atrophy who participated to the previous ISIS 396443 studies
To evaluate the long-term safety and tolerability of ISIS 396443 administered intrathecally to patients with SMA who previously participated in investigational studies of ISIS 396443.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301
The primary objective of the study is to assess the safety and tolerability of long-term treatment with DAC HYP monotherapy in subjects who completed Study 205MS301, Study 205MS203, or Study 205MS302
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
221AD302 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
Placebo-controlled period: To evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis Studio di fase I, multicentrico, in aperto, a braccio singolo, a dose multipla per valutare la farmacocinetica e la farmacodinamica di natalizumab in soggetti pediatrici con sclerosi multipla recidivante remittente
The primary objective of the study is to determine the PK profile of multiple doses of natalizumab in pediatric subjects with RRMS. L’obiettivo primario dello studio è di determinare il profilo ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies
The primary objective of the study is to determine the efficacy of Tysabri in subjects with relapsing forms of MS who have failed Gilenya or BRACET as measured by the proportion of subjects with no ev...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
221AD301 Phase 3 Study of Aducanumab in Early Alzheimer's Disease Estudio fase 3 de Aducanumab en pacientes con enfermedad de Alzheimer temprana
Placebo-controlled period: To evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Efficacy and Safety of Daclizumab in Participants with RRMS Switching from Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of BG00012-related GI AEs in subjects with MS.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant